Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report

INTRODUCTION: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound healing problems, gastrointestinal perforation, proteinuria and hypert...

Descripción completa

Detalles Bibliográficos
Autores principales: Uysal, Mukremin, Goksu, Sema Sezgin, Coskun, Hasan Senol, Savas, Burhan, Ozdogan, Mustafa, Bozcuk, Hakan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464779/
https://www.ncbi.nlm.nih.gov/pubmed/22776219
http://dx.doi.org/10.1186/1752-1947-6-188
Descripción
Sumario:INTRODUCTION: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound healing problems, gastrointestinal perforation, proteinuria and hypertension. CASE PRESENTATION: We present the case of a 65-year old Asian man with synovial metastasis of the knee who experienced intraarticular hemorrhage after bevacizumab treatment. He presented with monoarthritis of the left knee. CONCLUSION: Bevacizumab-related hemorrhage can cause serious morbidity and unusual sites of hemorrhage may be seen.

Ejemplares similares